Share on Facebook
Share on Twitter
Share on LinkedIn

A jury in the first federal trial over transvaginal mesh devices awarded $2 million on Thursday to a woman who alleged that the manufacturer failed to warn about defects in its product that caused her bleeding and pain.

Donna Cisson claims she had to undergo two surgeries to remove the device, one of C.R. Bard Inc.’s line of Avaulta products, which is inserted surgically into women to treat pelvic organ prolaspse – a condition that can cause urinary incontinence or pain, sometimes during sex.

Click here to read more.